Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts
Nkarta, Inc. (NASDAQ:NKTX – Get Rating) has been given a consensus rating of "Moderate Buy" by the nine ratings firms that are presently covering the stock, MarketBeat reports. One equities research
LXRX, PGNY and ANGI Are Among After Hour Movers
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of "Moderate Buy" by Brokerages
Nkarta, Inc. (NASDAQ:NKTX – Get Rating) has received an average rating of "Moderate Buy" from the nine analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst
Nkarta Promotes David Shook to Chief Medical Officer
Nkarta: Promotes David R. Shook, M.D., to Chief Medical Officer
EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Here is a look at the most
Nkarta, Inc. Forecasted to Post FY2024 Earnings of ($3.17) Per Share (NASDAQ:NKTX)
Nkarta, Inc. (NASDAQ:NKTX – Get Rating) – Investment analysts at Oppenheimer reduced their FY2024 earnings per share (EPS) estimates for shares of Nkarta in a report released on Thursday, December
Oppenheimer Lowers Nkarta (NASDAQ:NKTX) to Market Perform
Oppenheimer lowered shares of Nkarta (NASDAQ:NKTX – Get Rating) from an outperform rating to a market perform rating in a research note published on Thursday, Marketbeat.com reports. A number of othe
Nkarta (NASDAQ:NKTX) Downgraded by Oppenheimer
Oppenheimer downgraded shares of Nkarta (NASDAQ:NKTX – Get Rating) from an outperform rating to a market perform rating in a research note released on Thursday morning, Marketbeat reports. A number o
Market Prospects For Some Biotechs May Be Limited -- Market Talk
12:18 ET - Oppenheimer says it downgraded cell therapy names Fate Therapeutics, Celularity and Nkarta because it feels that in the treatment of diseases like lymphoma and myeloma, NK-cell therapies ar
Loading...
No Stock Yet